Heron Therapeutics Inc. shares surged 33.6% in premarket trade Thursday, after the company announced positive developments for its treatments for postoperative pain. The company said it has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for HTX-011, an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative pain. Breakthrough Therapy designation is aimed at speeding up the development and review of drugs that treat serious conditions and that show signs of offering significant improvement over existing therapies. Separately, Heron announced positive results in Phase 2b trials of HTX-011 in knee arthroplasty and breast augmentation, with the drug reducing pain intensity and lowering opioid use. Shares have gained 69.6% in the year through Wednesday, while the S&P 500 has gained 3.5%.

U.S. stock futures mostly lose ground early Thursday, putting the Dow Jones Industrial Average at risk of an eighth down session in a row.

Shares of Square Inc. are up 1.5% in premarket trading Thursday after Instinet's Dan Dolev raised his price target on the stock to $82 from $65. "The launch of Square for Restaurants marks Square's entry into the $650-700 billion U.S. restaurant industry," Dolev wrote. "We see at least ~30% potential upside to adj. revenue over a three-year period, a combination of payment processing revenue and cross-selling of ancillary software and services." He said that while all merchant acquirers have restaurant exposure, Global Payments Inc. seems "most at risk" to disruption by Square. Shares of Square are up 180% over the past 12 months, while the S&P 500 has gained 14%.

June has been chocked full of meetings that have shaken up investors, but now it is oil’s turn as OPEC revs up. Still, don’t bet you know the cartel so well, says our call of the day.

Retirees are thinking about risk all wrong

Kroger Co. shares soared 8.9% in Thursday premarket trading after the grocer reported first-quarter earnings that beat expectations and raised the low end of its guidance. Net income for the quarter totaled $2.03 billion, or $2.37 per share, up from $303.0 million, or 32 cents per share, for the same period last year. The gain includes the sale of the convenience store business, which added $1.59 per share. Adjusted EPS was 73 cents. Revenue was $37.5 billion, up from $36.3 billion last year. The FactSet consensus was for EPS of 63 cents and sales of $37.3 billion. Same-store sales excluding fuel rose 1.4%, while same-store sales including specialty pharmacy but excluding fuel rose 1.9%. The FactSet consensus was for 1.5% growth. Kroger expects 2018 same-store sales growth excluding fuel to range from growth of 2% to 2.5%, ahead of the FactSet consensus for 1.9% growth. And it raised the low end of its earnings guidance to a range of $3.64 to $3.79 from $3.59 to $3.79. Adjusted EPS is now expected to be in the range of $2.00 to $2.15, up from $1.95 to $2.15. The FactSet consensus is $2.75. Kroger shares are down 4.6% for the year to date, but up 17% for the past year. The S&P 500 index is up 3.5% for 2018 to date.

Shares of Advanced Micro Devices Inc. have gained nearly 30% in the past month, but the stock’s rapid rise hasn’t put to rest worries about the revenue AMD generates from cryptocurrency mining.

The two programs are closely matched in terms of value.

This man says he tried to find the son he fathered in his teens, but his son found him and discovered he was loaded.

European stocks fell Thursday, facing their fourth loss in five sessions, with auto shares under pressure and Italian shares flipping down following developments surrounding the country’s coalition government.